The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global long read sequencing market is expected to exhibit a CAGR of 23.4% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Long read sequencing (LRS) improves de novo assembly, mapping certainty, transcript isoform identification, and detection of structural variants. It also eliminates amplification bias while preserving base modifications. On account of these capabilities, LRS finds a broad range of applications in genomics for both model and non-model organisms. Moreover, compared to the next-generation sequencing (NGS) approach, LRS technology produces high-quality genome assemblies, captures clinically relevant genomic elements, and offers improvements in the characterization of genetic variation and regions.
The rising number of individuals suffering from genetic disorders, along with the increasing acceptance of modern approaches for medical diagnostics, represents one of the key factors bolstering the market growth. The escalating demand for LRS technology can also be attributed to its portability and real-time speed. It is also used to produce an accurate reference map of the centromere of the chromosomes. Apart from this, various biotech companies are developing innovative technologies that combine a new library prep method and genome analysis tools. In line with this, several studies indicate that LRS technology plays a crucial role in discovering novel pathogenic mutations in human diseases with unknown genetic causes. This presents numerous opportunities to researchers for using the technology in whole-genome sequencing (WGS) and enabling advancements in medical genetics. Furthermore, the rising utilization of sequence analysis methodologies in medical institutes for academic purposes, in confluence with the increasing investments in research and development (R&D) activities, is anticipated to drive the market growth further.
IMARC Group provides an analysis of the key trends in each sub-segment of the global long read sequencing market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on technology, product, application and end use.
Breakup by Technology:
Breakup by Product:
Breakup by Application:
Breakup by End Use:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being BaseClear B.V., Future Genomics Technologies B.V., Genexa AG, MicrobesNG, Oxford Nanopore Technologies Limited, Pacific Biosciences of California Inc., Promega Corporation, Quantapore Inc., Roche Sequencing (F. Hoffmann-La Roche AG), Takara Bio Inc. and Thermo Fisher Scientific Inc.
|Base Year of the Analysis||2021|
|Segment Coverage||Technology, Product, Application, End Use, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||BaseClear B.V., Future Genomics Technologies B.V., Genexa AG, MicrobesNG, Oxford Nanopore Technologies Limited, Pacific Biosciences of California Inc., Promega Corporation, Quantapore Inc., Roche Sequencing (F. Hoffmann-La Roche AG), Takara Bio Inc. and Thermo Fisher Scientific Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at